🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — March 25, 2026

A surge in US M&A and takeover activity dominates the week's filings, with 7 events spanning SPAC milestones (IPOs, amendments, unit separations), strategic acquisitions in food (FDP $285M Del Monte assets), cannabis (Vireo <4x EBITDA dispensaries/manufacturing), medtech (Lifeward amendment), and a mining divestiture (Hecla $160M cash + 65.8M shares + $321M contingent). Positive sentiment prevails in 5/7 filings (71%), with high materiality (avg 8/10) signaling portfolio-level M&A acceleration amid SPAC resurgence; no explicit YoY/QoQ revenue trends but deal-driven growth implied via platform expansions and low-multiple buys. Key developments include Hecla's deleveraging ($263M note redemption April 9) and FDP's brand reunion after 40 years, enhancing efficiency but flagging integration risks. Cross-company patterns show capital recycling (divest-to-acquire/reinvest), SPAC dry powder influx ($125M Blue Water IPO), and forward-looking catalysts like earnouts (Athena 25.5M shares) and dispensary scaling (Vireo to 75+). Implications: Bullish for M&A targets and post-deal synergies, watch SPAC closings for de-SPAC pops; sector tailwinds in cannabis/food/mining divestitures boost shareholder value via accretive deals.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 25, 2026

Across 50 overnight SEC filings, dominant themes include robust revenue growth in tech/AI firms (e.g., Pure Storage +16% YoY, Braze +24% YoY, Energous +633% YoY) offset by widespread margin compression and operating losses (8/15 tech filings showed opex rises >15% YoY), SPAC distress with heavy redemptions eroding trust balances (e.g., Concord Acquisition 99.6% trust drop), and positive M&A/deal momentum (Sandisk $1B investment, Thermon/CECO merger). Period-over-period trends reveal 12/25 revenue reporters posting YoY growth averaging +20% but only 4 achieving profitability flips (UiPath, AAR Corp); capital allocation leans toward dividends/buybacks (Zedge +25%, News Corp $1B program) amid mixed sentiments (22 mixed, 12 positive). Critical developments like Stratus Properties' liquidation plan (est. $29-38/share) and Maze Therapeutics' Phase 2 success signal high-volatility opportunities, while auditor changes (Brilliant N.E.V.) and litigation (C3.ai partial dismissal) flag governance risks. Portfolio-level patterns show tech outpacing resources/energy (avg revenue +18% vs flat/declining), with forward catalysts clustered in Q2 2026 (mergers, trials, meetings). Implications favor tactical longs in scaling tech/M&A plays and shorts on SPAC liquidity crunches before market open.

31 high priority 19 medium 50 total filings
· daily

Orphan Drug Approvals — March 24, 2026

FDA issued two Priority Review supplemental approvals with Orphan Drug designations on March 20, 2026, for Bristol Myers Squibb's OPDIVO (nivolumab) and Rhythm's IMCIVREE (setmelanotide acetate), signaling efficacy-driven label expansions into unspecified rare disease areas. These provide both companies with 7-year exclusivity and premium pricing potential, yielding moderately bullish signals for revenue growth in the orphan drug sector. Limited indication details constrain precise market sizing, warranting label monitoring for portfolio impact.

2 total filings
· daily

New Drug Approvals (Original) — March 24, 2026

Five FDA approvals on March 19, 2026—all under standard review with no special designations—yield a neutral overall signal, dominated by 4 generic ANDAs enabling routine market entries. Amneal Pharms NY stands out with a bullish original NDA for KITPROZY (carfilzomib), signaling new branded revenue potential amid otherwise commoditized generics. Investors should prioritize Amneal for near-term launch monitoring while viewing others as low-impact fillers in generic portfolios.

5 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 24, 2026

Across the four filings in the USA S&P 500 Technology stream, dominant themes include deleveraging and operational restructuring at Ucommune International Ltd, uplisting ambitions at First Northern Community Bancorp, and routine organizational and funding disclosures from Capital One Multi Asset Execution Trust and Federal Home Loan Bank of San Francisco. Ucommune reported sharp YoY declines with revenue down 66% to RMB 26.1M and total assets -38% to RMB 202.5M, but offset by cash +44% to RMB 36.1M, liabilities -57% to RMB 74.2M, operating loss narrowed 12% to RMB 40.6M, and net loss improved 51% to RMB 39.3M following VIE deconsolidation. First Northern's Nasdaq uplisting application signals growth intent, while FHLB SF's $371.5M bond issuance reflects stable funding at 4.000%-4.520% coupons with maturities 2027-2031. Capital One Trust filing is benign with no financial metrics. Portfolio-level patterns show 1/4 filings with improving loss metrics amid declines (outlier Ucommune turnaround), no insider activity or capital allocation trends, and neutral/mixed sentiment overall. Market implications favor monitoring uplisting catalysts and deleveraging for relative outperformance versus stagnant peers.

2 high priority 2 medium 4 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 24, 2026

The 7 filings reveal a bifurcated landscape in the NASDAQ-100 stream, with bullish operational and governance momentum in tech/AI (AITX, Intel) and uplisting potential (First Northern) offsetting sharp financial contraction at Ucommune and neutral housekeeping elsewhere. Key period-over-period trend outlier: Ucommune's revenue plunged 66% YoY to RMB 26.1M and assets declined 38% YoY to RMB 202.5M, though losses narrowed (operating -12% YoY to RMB 40.6M, net -51% YoY to RMB 39.3M) post-VIE deconsolidation. Positive sentiments dominate new filings (AITX expansion, Intel 'Reinventing' progress with Intel 18A/14A advancements, First Northern Nasdaq application), signaling portfolio-level growth in AI/security and governance refresh amid limited broader metrics. Critical developments include Intel's May 13, 2026 AGM for director elections and stockholder proposals on China/human rights risks, and FHLB's $371.5M bond issuance at 4.000-4.520% rates. Market implications: Favor AI/geographic expansion plays and monitor uplisters for liquidity alpha, while de-risking from Chinese-linked distress like Ucommune; no widespread margin/revenue trends due to sparse financial disclosures across filings.

3 high priority 4 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 24, 2026

Across 50 filings from S&P 500 Financials and adjacent sectors, proxy statements dominate (e.g., DEF 14A/DEFA14A) with neutral-to-positive governance themes, emphasizing independent boards, stock ownership compliance, and say-on-pay votes ahead of Apr-May 2026 AGMs. Revenue growth is a bright spot in 8/50 filings, averaging +52% YoY (e.g., Paysign +40.5%, FTC Solar +110.5%, Concentrix +5.4%), but profitability mixed with 6/12 earnings reporters showing margin compression (avg -150 bps) and widening losses (e.g., Achieve Life +37% YoY net loss, Vertical Aerospace op loss +108%). Capital allocation favors returns: dividends declared (Braemar, Concentrix), buybacks ($1B News Corp, Flowco $16.5M repurchase), note redemptions (Ready Capital). M&A catalysts include American Water's $Essential Utilities merger (Q1 2027 close) and Fundrise eREIT consolidations; Galaxy entities' 13Fs reveal heavy crypto/mining bets ($173M-$137B AUM across quarters). REITs shine (CareTrust +17% Normalized FFO, $1.76B deployment), but covenant waivers (FTC Solar, Inotiv) and going concerns (Ocean Thermal, Vertical) flag liquidity risks. Forward catalysts cluster in H1 2026: PDUFAs, AGMs, rate cases.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 24, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, personal care, and adjacent sectors), dominant themes include neutral-to-positive compliance assertions in 15+ mortgage trusts (e.g., Benchmark, JPMDB, CF series), signaling stable ABS servicing with no material non-compliance. Period-over-period trends show mixed performance: robust growth in outliers like Cadeler A/S (profit +330% YoY to €280M, EBITDA +238% to €425M) and Select Water Solutions (segment revenues +19% YoY), contrasted by declines in G-III Apparel (net sales -7% YoY to $2.96B, op profit -63%) and Velo3D (Q4 rev -25% YoY, gross margin -73.6%). Capital allocation highlights dividend declarations (Braemar Hotels) and debt refinancings (Moog +5.5% notes, Kodiak 5.875% notes), while M&A speculation emerges in Estée Lauder (potential Puig merger, materiality 9/10). Portfolio-level patterns reveal 6/10 high-materiality filings with mixed sentiment due to growth-margin tradeoffs, 12+ proxy statements clustering AGMs in May 2026 for governance catalysts, and financing inflows supporting expansion amid rising indebtedness (e.g., Cadeler debt to €1.46B). Overall, actionable intelligence points to monitoring beauty M&A and energy-adjacent growth amid apparel weakness, with no widespread insider selling but leadership transitions signaling potential volatility.

39 high priority 11 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 24, 2026

Across 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, with extraneous financial/mortgage trusts and proxies), overarching themes include routine Regulation AB compliance affirmations in 15+ mortgage trusts (all neutral/positive, no non-compliance), proxy season ramp-up for May 2026 AGMs (10+ filings), and mixed financial results in operating companies highlighting resilience in transportation (C.H. Robinson EPS +25.1% YoY despite revenues -8.4%) amid broader sector softness. Period-over-period trends reveal divergent performance: explosive growth in niche players like Cadeler A/S (profit +330% YoY to €280.2M, EBITDA +238%) and Fennec Pharmaceuticals (product sales +50% YoY to $44.6M), contrasted by declines in apparel/transport (G-III sales -7% YoY, Neurogene net loss widened 20% YoY to $90.4M). No insider trading activity disclosed across filings, limiting conviction signals; capital allocation shows distributions funded by cash flows (Cantor Fitzgerald) or proceeds (Strategic Storage +8.6% YoY), with debt increases (Cadeler net indebtedness +181% to €1.46B). Critical developments include M&A discussions (Estée Lauder/Puig), leadership transitions (Bitcoin Depot new CEO, QuidelOrtho CLO), and clinical catalysts (Neurogene Embolden trial dosing Q2 2026). Portfolio-level patterns flag Industrials outperformance in profitability metrics vs. revenue (e.g., C.H. Robinson ops income +18.8% YoY), with opportunities in undervalued turnarounds amid proxy-driven governance focus.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 24, 2026

Across the S&P 500 Energy sector filings, key themes include management continuity at Chesapeake Utilities (CPK) via a seamless CFO transition and Devon's proactive balance sheet strengthening through credit extension and merger progress with Coterra. No period-over-period declines, flat metrics, or adverse financial trends were reported in any filing, signaling operational stability amid positive sentiments in 2/3 filings. Devon's dual filings highlight material catalysts: a tax-free merger targeted for Q2 2026 close and credit maturity extension to March 24, 2031, with potential borrowing cost reductions via 10bps SOFR spread removal. CPK's executive change underscores confidence in sustained earnings growth and balance sheet strength post-transition on July 1, 2026. Portfolio-level implications point to improving liquidity and M&A momentum in oil & gas E&P, positioning Devon as a sector consolidator while CPK exemplifies utility-like stability in energy distribution. Overall, bullish undertones dominate with no guidance cuts or insider selling detected.

2 high priority 1 medium 3 total filings
· daily

US Material Events SEC 8-K Filings — March 24, 2026

Across 50 SEC filings from March 24, 2026, a dominant theme is widespread leadership transitions in 22 companies (44%), including 12 positive appointments/promotions (e.g., Rush Enterprises COO, Bitcoin Depot CEO), 8 neutral retirements/resignations, and clustered CFO departures at 5 New Mountain entities, signaling potential continuity risks but often smooth internal successions. Financing activities dominate 18 filings (36%), with positive extensions/increases (e.g., Innodata credit to $50M, Portland GE $350M loan) contrasting mixed covenant waivers/debt restructurings (e.g., FTC Solar $10M repayments, Southland $110M assignment), reflecting liquidity management amid uncertain macro conditions. Capital allocation shines with Robinhood's $1.5B buyback authorization (adding $1.1B capacity) and LSI's accretive $325M acquisition (pro forma EBITDA margin up to 11% from 9.7%), while period trends show mixed results: Velo3D revenue +12% YoY to $46M but margins -1100 bps to -16.1%; Cardlytics pro forma revenue -9% but net losses improved 12-79%. M&A/divestitures in 4 filings (LSI, Cardlytics, Krispy Kreme $160M proceeds) support deleveraging/turnarounds, with positive sentiments in 60% of filings. Portfolio-level implications: Bullish for stable leadership/financing in utilities/fintech, cautious on manufacturing/tech margin pressures; watch H1 2026 catalysts like FTC Solar covenants and Velo3D EBITDA positivity.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 24, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily small/mid-cap and trusts with DJ30-adjacent themes like Intel, eBay), overarching themes include biotech regulatory catalysts, SPAC/M&A pursuits, private credit expansions, energy trust depletions, and governance proxies. Period-over-period trends reveal bimodal patterns: explosive growth in AI/biotech (Blaize revenue +24x YoY to $38.6M, Audax portfolio +46% to $949.8M) contrasted by sharp declines in energy royalties (MV Oil income -39% YoY to $11.3M, VOC -37% to $8.6M) and biotech losses (Achieve +37% to $54.6M). Credit funds show portfolio growth but yield compression (Audax 8.28% vs 10.07% prior), while SPACs highlight PIPE evaluations amid redemption risks. Critical developments: Achieve PDUFA June 20 2026, Blaize FY26 $130M revenue guide, Thermon/CECO merger synergies for 20%+ EBITDA. Portfolio-level patterns: 6/10 high-materiality mixed sentiments driven by cash raises vs burns; capital allocation favors distributions (Golub $0.1875/share) over buybacks; no widespread insider trading but heavy shelves/ATMs signal dilution risks. Market implications: Bullish AI/biotech catalysts, bearish energy depletion, monitor SPAC closings for volatility.

30 high priority 20 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 24, 2026

Across 50 SEC filings for March 24, 2026, key themes include robust revenue growth in niche sectors like patient affordability (Paysign +40.5% YoY), solar trackers (FTC Solar +110.5% YoY), and infrastructure (Smith-Midland prelim +18-25% FY), contrasted by persistent net losses and margin pressures in biotech, tech services, and media (e.g., Bright Mountain Q4 revenue -8% YoY, gross margin -23%). REITs and utilities shone with strong FFO growth (CareTrust +17% YoY) and rate case settlements (NW Natural +$20.1M Year 1 rev), while multiple debt waivers/amendments (FTC Solar, Inotiv) signal liquidity strains amid high interest expenses. Biotech advancements provide catalysts like Achieve Life's PDUFA on June 20, 2026, and M&A rumors (Estee Lauder-Puig, American Water-Essential Utilities Q1 2027 close) dominate headlines. Galaxy entities' 13F filings reveal massive crypto/mining concentration ($ billions in Bitcoin ETFs, miners like CleanSpark, Core Scientific), indicating bullish institutional conviction in digital assets. Capital allocation favors dividends (Concentrix $0.36 Q, Braemar prefs) and buybacks (News Corp $1B program, Flowco $16.5M repurchase), with shelf offerings/ATMs (Artelo, Aardvark $150M) for fundraising. Overall, mixed sentiment prevails (28/50 mixed/neutral), with portfolio-level trends showing revenue acceleration (avg +30% YoY in 8 growth names) but EBITDA/margin volatility, urging focus on catalysts amid delisting risks in microcaps.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 24, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly encompassing retail, services, and adjacent sectors), overarching themes include robust revenue growth in select growth names (avg +50% YoY across 12 cos with data, e.g., FTC Solar +110.5%, Fennec +50%) offset by widening net losses (avg +40% YoY in 10 cos) due to op ex surges (e.g., Achieve +41%) and one-time hits; heavy capital allocation toward buybacks (Robinhood +$1.5B) and dividends (Braemar, Golub); M&A/reorg activity (UniFirst/Cintas H2 2026 close, Fundrise mergers, Digimarc reorg); and a wave of proxy filings signaling April-May 2026 meetings. Period-over-period trends reveal portfolio expansion in credit funds (Audax +46%, HPS +118%) and improving cash in biopharma (Achieve +64% cash), but deteriorating margins in solar/manufacturing amid debt pressures. Critical developments like Achieve's PDUFA June 20, 2026, and FTC Solar's covenant waivers imply near-term catalysts, while multiple CFO resignations at New Mountain entities signal leadership flux. Sector implications point to resilient consumer-related demand (e.g., G Willi Food +6% rev, +29% NI) but vulnerability to costs/debt in cyclical plays, favoring buyback-heavy names for near-term returns.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 24, 2026

Across the USA S&P 500 Healthcare stream's 36 filings, biotech and medtech firms dominate with mixed sentiment: clinical advancements and FDA milestones offset widening net losses (avg +25% YoY across Achieve, Absci, Artelo) driven by 25-40% YoY op ex surges amid flat/declining revenues. S&P 500 heavyweights like Medtronic, Centene, and Thermo Fisher show strategic progress—FDA clearance, leadership promotions, and M&A completion—but face short-term EPS dilution and charges. Cash positions strengthened via financings (e.g., Absci $144M to H1 2028, Achieve $36M up 6% YoY), supporting runways through 2027-2028, while capital allocation leans toward R&D reinvestment over dividends/buybacks. Key portfolio trends: 4/7 core healthcare cos reported loss expansion despite asset growth (avg +5% YoY), with H1-H2 2026 catalysts clustering around PDUFAs, trial data, and launches. Non-health filings (e.g., mortgage trusts, FHLBs) neutral, highlighting compliance and debt issuance but irrelevant to sector. Implications: tactical longs on catalysts, hedge burn risks; relative outperformance in clinical progress vs. financial deterioration.

20 high priority 16 medium 36 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 24, 2026

Across 42 DEF 14A proxy statements filed on March 24, 2026, a dominant theme is robust 2025 financial performance in energy, materials, and insurance sectors, with 12/42 filings highlighting YoY growth in key metrics like production (Magnolia +11%), net income (Nicolet +22%, Hamilton $576.7M), and cash flow (Albemarle OCF +86%, Eastman $1B). Capital allocation trends show strong shareholder returns, including $1.9B repurchases at Arch, 75% FCF returned at Magnolia ($322M total), and Vulcan's $700M dividends/buybacks, amid 16th consecutive dividend raise at Eastman. Mixed signals emerge in logistics (CH Robinson revenues -8.4% YoY but EPS +25.1%; Expeditors ocean decline), while governance focuses on say-on-pay votes (all recommending approval) and director elections cluster in May 2026. Notable M&A includes American Water's $3.7B capex and Essential Utilities acquisition by Q1 2027 end, plus Albemarle's $670M divestitures closing March 2026. Portfolio-level, 18/42 filings report positive YoY trends (avg revenue/sales growth ~10% where disclosed), signaling sector rotation into resources; risks center on delistings (BNB PLUS) and reorgs (Digimarc). Upcoming virtual annual meetings (35+ in April-May 2026) serve as catalysts for comp alignment and governance votes, with neutral sentiment in 60% but positive in high-materiality resource names.

42 high priority 42 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 24, 2026

Four S-1 filings on March 24, 2026, underscore a diverse IPO pipeline: a new SPAC (Research Alliance Corp III), post-IPO amendment for Forgent Power Solutions (IPO closed Feb 6), proposed IPO for Arxis, and resale registration for biotech Artelo Biosciences amid distress signals. Overarching themes include standard SPAC protections, acquisition-driven asset buildup in power sector (FPS intangibles from PwrQ/States/VanTran/MGM), extensive regulatory/compliance risks (Arxis FCPA/ITAR/FAA), and dilution/Nasdaq pressures (Artelo 1-for-3 reverse split reducing shares 65% from 2.12M to 736K). No uniform period-over-period trends across filings, but FPS flags Q4 2025 customer concentration risk in revenue/accounts receivable, contrasting neutral sentiment in SPAC/FPS vs negative in Arxis and mixed in Artelo. Critical developments like FPS over-allotment options (Feb 9) and Artelo Nasdaq extension to March 30 imply near-term catalysts, with high materiality (9-10/10) signaling investor attention. Portfolio-level pattern: 75% neutral/mixed sentiment suggests resilient IPO momentum despite biotech distress, positioning SPACs/power plays for alpha amid aerospace/biotech hurdles.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — March 24, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include ongoing insolvency proceedings in 6+ Indian firms (e.g., Future Lifestyle, Punj Lloyd, Unitech International), signaling distress in retail, pharma, and construction sectors; multiple open offers/takeovers (Rekvina Labs, Photon Capital, Aar Shyam) indicating consolidation plays; and widespread trading window closures starting April 1, 2026, ahead of Q4/FY2026 earnings for energy/refinery firms like MRPL, Godavari, Jagsonpal. US-centric 10-K/20-F reports show mixed financials: revenue surges (FTC Solar +110.5% YoY to $99.7M, Audax portfolio +46% to $949.8M) offset by widening losses or going concern doubts (Vertical Aerospace operating loss +108% to £127M, Ocean Thermal net loss $69.3M), while capital returns shine with TVS Motor's ₹570 Cr dividend (₹12/share) and Arch Capital's $1.9B buybacks. Period-over-period trends reveal improving gross margins (FTC Solar -0.9% vs -26.6% prior) but rising op expenses/R&D in tech/energy (Vertical R&D +20% YoY); insider policies strict but no transaction data signals conviction shifts. Portfolio-level, 7/15 annual reports show revenue growth averaging +45% YoY but net losses in 9/15 (avg widening 20-100%), with M&A/amalgamations (Torrent-JB Chemicals) and ATM facilities (Aardvark $150M) as catalysts. Implications: monitor Indian insolvencies for distress alpha, US solar/energy for turnaround bets, and earnings catalysts mid-April-May for volatility.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — March 24, 2026

Across 50 filings dated March 24, 2026, primarily FY2025 10-Ks, sentiment is predominantly mixed (24/50) or neutral (18/50), with operating companies showing divergent trends: explosive revenue growth in solar (FTC Solar +110.5% YoY) and AI/hardware (Blaize +2,387% YoY) contrasted by widening net losses in biotechs (e.g., COMPASS +85.6%, Fractyl +105%, Neurogene +20.2%) and sharp declines in energy trusts (VOC -37% income, MV Oil -39%). Retail outliers like GameStop delivered +218.7% net income surge despite -5.1% sales drop via margin expansion (+7.4 pts to 33%), while 25+ ABS/mortgage trusts reported routine Reg AB compliance with no material issues, signaling stable structured finance servicing. Portfolio-level trends reveal biotech cash burn averaging +30% YoY (e.g., Achieve +37%, Neurogene +9.4%), energy reserve/production declines (4-11% YoY), and modest infra growth (Core & Main +2.8% sales). Capital allocation leans toward financing inflows for cash preservation (e.g., FTC +$40.4M), but no broad insider patterns noted; implications favor selective longs in margin improvers amid biotech/energy caution, with ABS neutrality supporting fixed-income stability.

50 high priority 50 total filings